Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MN provider‑administered dr…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MinnesotaPolicy N/A

    Provider-Administered Precertification Drug List

    Customize your policy alerts

    Sign up for all blue cross blue shield - minnesota policy alerts

    Know when blue cross blue shield - minnesota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    List of provider-administered drugs that require precertification when given in a provider office, outpatient facility, or home health setting; gene therapy/cellular immunotherapy products require precertification regardless of setting. Affects providers administering these drugs to Blue Cross Blue Shield - Minnesota members.

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification prior to administering any drug on the list in a provider office, outpatient facility, or home health setting; products marked '+' require precertification in any setting.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~400drugs listed
    monthlyupdate frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    all settings
    gene therapy PA
    oncology-onlyAvastin PA

    Precertification Coverage Criteria

    Precertification criteria

    Covered when ALL of the following are met

    Precertification requirement: Drug is on the Provider-Administered Precertification Drug List

    List enumerates specific products; see source list

    Setting requirement: For drugs on the list: administered in a provider's office, outpatient facility, or home health setting requires precertification; for products marked with '+': precertification is required in any place of treatment

    Gene therapy/cellular immunotherapy products are indicated with '+' and have broader setting requirement

    For Avastin, precertification is required for oncology indications only. This is an exception to the general precertification requirement on the Provider‑Administered Precertification Drug List and applies regardless of the setting.

    Provider Responsibilities & Prior Authorization Requirements

    Prior Authorization

    Precertification required for listed provider-administered drugs

    Precertification (prior authorization) must be obtained for drugs on the Provider-Administered Precertification Drug List when they are administered in a provider's office, outpatient facility, or home health setting. Products designated as Gene Therapy/Cellular Immunotherapy (marked with a +) require precertification in any place of treatment.

    Note

    Gene therapy/cellular immunotherapy and list updates

    Treatments marked with a '+' are Gene Therapy/Cellular Immunotherapy products and require precertification regardless of treatment setting; the drug list is updated monthly and subject to change.

    Documentation Required

    Documentation and setting requirements for precertification

    Providers must obtain precertification prior to administration for drugs on the list when given in a provider's office, outpatient facility, or home health setting. For Gene Therapy/Cellular Immunotherapy products (marked with +), precertification is required for administration in any place of treatment.

    Denial Risk

    Denial risk if precertification is not obtained

    Lack of the required precertification for listed provider-administered drugs when given in a provider's office, outpatient facility, or home health setting may result in denial of coverage or claim processing delays.

    Applicable Treatment Settings

    Step Therapy

    Site-of-care precertification requirement

    Precertification is required when these drugs are administered in a provider's office, outpatient facility, or home health setting; gene therapy/cellular immunotherapy products (marked with +) require precertification in any place of treatment.

    • Settings called out: provider's office, outpatient facility, home health (home)
    • Gene therapy/cellular immunotherapy (+) precertification applies in all settings

    Definitions and Notation

    Gene Therapy/Cellular Immunotherapy (+)
    DefinitionGene Therapy/Cellular Immunotherapy products are indicated by a '+' and require precertification regardless of treatment setting.
    Symbol meaning'+' placed after a product name designates it as a Gene Therapy/Cellular Immunotherapy product.
    Precertification scopeProducts marked with '+' require precertification when administered in any place of treatment (all settings).
    Document typeThis is an administrative provider‑administered precertification list, not clinical guidance.
    List maintenanceThe product list is updated monthly and is subject to change without notice.

    Background and Scope

    This document functions as an administrative precertification list, not clinical guidance. It identifies products that are subject to the Provider‑Administered Drug Review Program and specifies which drugs require precertification prior to administration. The list is updated monthly and notes that gene therapy/cellular immunotherapy products are identified with a '+' and require precertification in all settings.

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification prior to administering any drug on the list in a provider office, outpatient facility, or home health setting; products marked '+' require precertification in any setting.
    SourceLink
    On This Page
    Precertification Coverage CriteriaProvider Responsibilities & Prior Authorization RequirementsApplicable Treatment SettingsDefinitions and NotationBackground and Scope